Urgent-SQ implant in treatment of overactive bladder syndrome: 9-year follow-up study

2012 ◽  
Vol 32 (5) ◽  
pp. 472-475 ◽  
Author(s):  
Dick A. Janssen ◽  
Fawzy Farag ◽  
John P. Heesakkers
Keyword(s):  
Overactive Bladder ◽  
Overactive Bladder Syndrome ◽  
Follow Up Study

Antimuscarinic Use in Females With Overactive Bladder Syndrome Increases the Risk of Depressive Disorder: A 3-Year Follow-up Study

2017 ◽  
Vol 57 (8) ◽  
pp. 1064-1070 ◽  
Author(s):  
Shiu-Dong Chung ◽  
Sung-Shun Weng ◽  
Chao-Yuan Huang ◽  
Herng-Ching Lin ◽  
Li-Ting Kao
Keyword(s):  
Overactive Bladder ◽  
Depressive Disorder ◽  
Overactive Bladder Syndrome ◽  
Follow Up Study

Implant-Driven Tibial Nerve Stimulation in the Treatment of Refractory Overactive Bladder Syndrome: 12-Month Follow-up

2006 ◽  
Vol 9 (2) ◽  
pp. 163-171 ◽  
Author(s):  
Floor van der Pal ◽  
Michael R. van Balken ◽  
John P. F. A. Heesakkers ◽  
Frans M. J. Debruyne ◽  
Bart L. H. Bemelmans
Keyword(s):  
Overactive Bladder ◽  
Nerve Stimulation ◽  
Tibial Nerve ◽  
Overactive Bladder Syndrome ◽  
Tibial Nerve Stimulation

scholarly journals Efficacy of Transdermal Oxybutynin in the Treatment of Overactive Bladder Syndrome: Does It Make Sense Using It in 2017?

2018 ◽  
Vol 2018 ◽  
pp. 1-7 ◽  
Author(s):  
Raúl Vozmediano-Chicharro ◽  
Blanca Madurga ◽  
Pedro Blasco
Keyword(s):  
Overactive Bladder ◽  
Adverse Events ◽  
Application Site ◽  
Overactive Bladder Syndrome ◽  
Good Tolerability ◽  
Subgroup Analyses ◽  
Voiding Diary ◽  
Previously Treated ◽  
Clinical Records

Objectives. Evaluation of changes in symptoms among patients with overactive bladder syndrome treated with transdermal oxybutynin and tolerability after 12 months of follow-up. Methods. This was a multicenter, retrospective, single-cohort, observational study. Changes in symptoms were evaluated primarily with a 3-day voiding diary. Results were compared to baseline. Subgroup analyses were performed in patients previously treated for OAB or not and aged < 65 years versus ≥65 years. Results. Clinical records of 105 patients were examined; 92.4% were women. At 12 months, 58 patients continued to receive transdermal oxybutynin. Changes in symptoms according to the voiding diary were evaluated in 47 patients. Significant improvements from baseline were observed in urinary frequency (−2.6 voids/24 hours (95% CI: −3.5; −1.8), p<0.001); daily number of urgent episodes (−4.7 episodes/day (95% CI: −6.1; −3.6), p<0.001); and urge incontinence (−1.9 episodes/day (95% CI: −2.9; −1.3), p<0.001). No statistically significant differences were found in subgroup analyses. In total, 38.1% of patients had adverse events, primarily in the application site (27.6%). No severe systemic adverse events occurred. Only 6 patients (5.7%) reported dry mouth. Conclusions. Improved symptoms and good tolerability observed after 1 year of treatment with transdermal oxybutynin shows that it currently has a place in the treatment of OAB patients.

scholarly journals The impact of urodynamics on treatment and outcomes in women with an overactive bladder: a longitudinal prospective follow-up study

2017 ◽  
Author(s):  
Tina Sara Verghese ◽  
Lee J. Middleton ◽  
Jane P. Daniels ◽  
Jonathan J. Deeks ◽  
Pallavi Manish Latthe
Keyword(s):  
Overactive Bladder ◽  
Follow Up Study ◽  
The Impact
Sign in / Sign up

Export Citation Format

Share Document